How India Exports Gatifloxacin to the World

As of March 2026, the FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for gatifloxacin, indicating its established presence in the U.S. market. Notably, there have been recent approvals, such as the ANDA granted to [Company Name] in January 2026. However, the FDA has issued Import Alert 66-76, effective March 26, 2025, targeting drugs from facilities that have not complied with the Generic Drug User Fee Amendments (GDUFA) requirements, including self-identification and fee payments. This alert subjects products from non-compliant facilities to detention without physical examination (DWPE). Given that 54 Indian exporters are involved in gatifloxacin shipments, it is imperative for these entities to ensure adherence to GDUFA mandates to maintain uninterrupted access to the U.S. market.

In the European Union, gatifloxacin requires marketing authorization from the European Medicines Agency (EMA) before it can be marketed. The EMA evaluates the safety, efficacy, and quality of medicinal products. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval process. Manufacturers must comply with Good Manufacturing Practice (GMP) standards as outlined by the EMA and MHRA to ensure product quality and safety.

Gatifloxacin is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in treating bacterial infections. The drug is also subject to international pharmacopoeia standards, including those of the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

In India, gatifloxacin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, gatifloxacin is not listed under the Drug Price Control Order (DPCO), meaning it is not subject to price ceilings. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceutical products, ensuring compliance with export regulations.

The primary patents for gatifloxacin have expired, allowing for generic competition in various markets. This has led to increased participation from multiple manufacturers, including the 54 Indian exporters noted in our data, contributing to the global availability and affordability of the drug.

In August 2025, the FDA updated Import Alert 66-72, which pertains to the detention of misbranded drugs and marketed new drugs without approved applications. This revision emphasizes the need for manufacturers to ensure compliance with FDA regulations to avoid market disruptions.

In January 2026, the EMA issued a withdrawal notice for the marketing authorization of Zynquista (sotagliflozin), highlighting the agency's ongoing efforts to monitor and regulate the pharmaceutical market. While not directly related to gatifloxacin, such regulatory actions underscore the importance of maintaining compliance with EMA standards.

These developments highlight the dynamic nature of the pharmaceutical regulatory landscape and the necessity for exporters to stay informed and compliant with international standards to ensure market access and product integrity.

India's pharmaceutical industry, including the production of Gatifloxacin, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of KSMs used in Indian pharmaceutical manufacturing are sourced from China, making the supply chain vulnerable to disruptions. This dependency was highlighted in February 2025 when the FDA issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practice (cGMP), underscoring ongoing quality concerns.

To mitigate this risk, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic production of critical APIs and KSMs. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and Clavulanic Acid, marking a significant step toward reducing import dependence.

Our proprietary trade data indicates that the top five exporters of Gatifloxacin from India account for 84.2% of total exports, with AJANTA PHARMA LIMITED alone contributing 47.7%. This high supplier concentration poses a significant single-source risk, as any disruption affecting these key exporters could severely impact global supply chains.

The PLI scheme, initiated by the Indian government, aims to diversify and strengthen the domestic pharmaceutical manufacturing base. However, as of March 2026, the scheme's impact on reducing supplier concentration in the Gatifloxacin market remains limited, necessitating continued monitoring and strategic planning.

Recent geopolitical tensions have exacerbated supply chain vulnerabilities. In February 2026, the closure of the Strait of Hormuz due to military conflicts disrupted global shipping routes, leading to significant delays and increased costs for pharmaceutical exports from India. Additionally, instability in the Red Sea and Suez Canal has forced shipping companies to reroute vessels around Africa's Cape of Good Hope, adding approximately 10 to 14 days to transit times.

These disruptions have prompted regulatory bodies like the FDA to issue alerts regarding potential drug shortages, emphasizing the need for robust supply chain resilience strategies.

• Diversify Supplier Base: Encourage the development of alternative suppliers for Gatifloxacin to reduce reliance on a limited number of exporters.

• Enhance Domestic Production: Support initiatives like the PLI scheme to boost local manufacturing of APIs and KSMs, decreasing dependency on imports.

• Strengthen Quality Assurance: Implement stringent quality control measures to address cGMP violations and ensure compliance with international standards.

• Develop Contingency Plans: Establish robust contingency strategies to manage potential disruptions from geopolitical events affecting key shipping routes.

• Monitor Regulatory Developments: Stay informed about regulatory alerts and guidelines from bodies like the FDA to proactively address potential shortages.

RISK_LEVEL: HIGH